Abdullah M. Khan, MBBS, assistant professor in the Department of Hematology at The Ohio State University Comprehensive Cancer Center – The James, presents a recent update on data on the use of idecabutagene viclucel (ide-cel; Abecma) in relapsed/relapsed patients. This section explains. Refractory multiple myeloma.
Latest data from the pivotal phase 3 KarMMa-3 trial (NCT03651128) that led to the approval of this chimeric antigen receptor T-cell therapy was reported at the 2023 American Society of Hematology Annual Meeting and Exposition. At 30.9 months of follow-up, researchers reported interim overall survival (OS) data, with median OS of 41.4 months in the ide-cel arm versus 37.9 months in the standard-of-care arm. It was shown that
Additionally, Khan pointed out that real-world evidence using ide-cel has been reported. Journal of Clinical Oncology In 2023, we will support its use in patients who do not necessarily meet the strict patient eligibility requirements of clinical trials. Among the 159 patients who received ide-cel, the best overall response rate was 84%, with a median progression-free survival (PFS) of 8.5 months (95% CI, 6.5 not reached). In comparison, the median OS was 12.5 months (95%). CI, 11.3 – not reached).
These are all promising sources of data showing the benefits of ide-cel, including in patients with comorbidities receiving CAR T-cell therapy in the real world, Khan said.
Transcription:
0:08 | I would like to share some of the latest data from the ASH 2023 conference. In fact, we have survival data from his KarMMa-3 trial with long-term follow-up of approximately 31 months. What they were able to prove was that the median OS for the ide-cel group was 41.4 months, compared to 37.9 months for the standard group. [therapy] group.
0:38 | There was also a recent publication that talked about ide-cel in the real world. In the real world, trial designs have fairly strict inclusion and exclusion criteria, so we don’t often apply those rules to patients seen in the clinic. And a recent paper published at his JCO in 2023 showed an excellent response rate of about 84% in 159 patients. …In these less ideal patients…for trial candidates, median PFS was 8.5 months and median OS was 12.5 months. Again, this is very promising data, not just from trials but from real-world data as well.